The Journal of Urology
Volume 184, Issue 3 , Pages 842-850 , September 2010

HER-2/neu Expression in Prostate Adenocarcinoma: A Systematic Review and Meta-Analysis

  • Ary Serpa Neto

      Affiliations

    • Urologic Oncology Division, Department of Urology, ABC Medicine School, Santo André, São Paulo, Brazil
    • ,
  • Marcos Tobias-Machado

      Affiliations

    • Urologic Oncology Division, Department of Urology, ABC Medicine School, Santo André, São Paulo, Brazil
    • Research Institute, Albert Einstein Jewish Hospital, São Paulo, Brazil
    • ,
  • Marcelo Langer Wroclawski

      Affiliations

    • Urologic Oncology Division, Department of Urology, ABC Medicine School, Santo André, São Paulo, Brazil
    • Research Institute, Albert Einstein Jewish Hospital, São Paulo, Brazil
    • ,
  • Fernando Luiz Affonso Fonseca

      Affiliations

    • Oncology Division, Department of Clinical Oncology and Hematology, ABC Medicine School, Santo André, São Paulo, Brazil
    • ,
  • Gabriel Kushiyama Teixeira

      Affiliations

    • Urologic Oncology Division, Department of Urology, ABC Medicine School, Santo André, São Paulo, Brazil
    • ,
  • Rodrigo Dal Moro Amarante

      Affiliations

    • Urologic Oncology Division, Department of Urology, ABC Medicine School, Santo André, São Paulo, Brazil
    • ,
  • Eric Roger Wroclawski

      Affiliations

    • Urologic Oncology Division, Department of Urology, ABC Medicine School, Santo André, São Paulo, Brazil
    • Research Institute, Albert Einstein Jewish Hospital, São Paulo, Brazil
    • ,
  • Auro Del Giglio

      Affiliations

    • Oncology Division, Department of Clinical Oncology and Hematology, ABC Medicine School, Santo André, São Paulo, Brazil
    • Research Institute, Albert Einstein Jewish Hospital, São Paulo, Brazil
    • Corresponding Author InformationCorrespondence: Department of Hematology and Oncology, ABC Medicine School, Oncology Department, Albert Einstein Jewish Hospital, Rua Mariana Correia, 369-CEP 01400-000-São Paulo, São Paulo, Brazil (telephone and FAX: + 55-11-38195007)

Received 17 November 2009

References 

  1. Beerli RR, Graus-Porta D, Woods-Cook K, et al. Neu differentiation factor activation of erbB-3 and erbB-4 is cell specific and displays a differential requirement for erbB-2. Mol Cell Biol. 1995;15:6496
  2. De Laurentiis M, Arpino G, Massarelli E, et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res. 2005;11:4741
  3. Lonardo F, Di Marco E, King CR, et al. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. New Biol. 1990;2:992
  4. Hede K. Gastric cancer: trastuzumab trial results spur search for other targets. J Natl Cancer Inst. 2009;101:1306
  5. Berger R, Lin DI, Nieto M, et al. Androgen-dependent regulation of HER-2/neu in prostate cancer cells. Cancer Res. 2006;66:5723
  6. Craft N, Shostak Y, Carey M, et al. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signalling by the HER-2/neu tyrosine kinase. Nat Med. 1999;5:280
  7. Mellinghoff IK, Vivanco I, Kwon A, et al. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell. 2004;6:517
  8. Signoretti S, Montironi R, Manola J, et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst. 2000;92:1918
  9. Yuan CX, Lasut AL, Wynn R, et al. Purification of Her-2 extracellular domain and identification of its cleavage site. Protein Expr Purif. 2003;29:217
  10. Christianson T, Doherty JK, Lin YJ, et al. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res. 1998;58:5123
  11. Molina MA, Codony-Servat J, Albanell J, et al. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 2001;61:4744
  12. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719
  13. Krouwer JS, Monti KL. A simple, graphical method to evaluate laboratory assays. Eur J Clin Chem Clin Biochem. 1995;33:525
  14. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455
  15. Wen Y, Hu MC, Makino K, et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res. 2000;60:6841
  16. Arai Y, Yoshiki T, Yoshida O. c-erbB-2 oncoprotein: a potential biomarker of advanced prostate cancer. Prostate. 1997;30:195
  17. Domingo-Domenech J, Fernandez PL, Filella X, et al. Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel. Ann Oncol. 2008;19:269
  18. Okegawa T, Kinjo M, Nutahara K, et al. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. Int J Urol. 2006;13:1197
  19. Shariat SF, Bensalah K, Karam JA, et al. Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer. Clin Cancer Res. 2007;13:5377
  20. Fantinato AP, Tobias-Machado M, Fonseca F, et al. Her2/neu expression by reverse transcriptase-polymerase chain reaction in the peripheral blood of prostate cancer patients. Tumori. 2007;93:467
  21. Croal BL, Mitchell IDC, Mutch WJ, et al. Serum HER-2/neu extracellular domain levels in men presenting with suspected prostate cancer. UroOncology. 2002;2:99
  22. Boglou K, Valeri RM, Dimasis N, et al. Serum level detection of HER2/neu in patients with prostatic hyerplasia and prostate cancer. Cytopathology. 2008;19(suppl.):63;abstract 136
  23. Osman I, Mikhail M, Shuch B, et al. Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression. J Urol. 2005;174:2174
  24. Myers RB, Brown D, Oelschlager DK, et al. Elevated serum levels of p105(erbB-2) in patients with advanced-stage prostatic adenocarcinoma. Int J Cancer. 1996;69:398
  25. Ziada A, Barqawi A, Glode LM, et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate. 2004;60:332
  26. Lara PN, Chee KG, Longmate J, et al. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer. 2004;100:2125
  27. de Bono JS, Bellmunt J, Attard G, et al. Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol. 2007;25:257
  28. Agus DB, Sweeney CJ, Morris MJ, et al. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol. 2007;25:675

 Supplementary material for this article can be obtained at http://rapidshare.com/files/331390528/Table.pdf.html and http://rapidshare.com/files/339504949/Appendix.pdf.html.

PII: S0022-5347(10)03512-3

doi: 10.1016/j.juro.2010.04.077

The Journal of Urology
Volume 184, Issue 3 , Pages 842-850 , September 2010

Article Tools

* Image Usage & Resolution